Wiltschke C, Kindas-Muegge I, Steininger A, Reiner A, Reiner G, Preis P N
Department of Internal Medicine I, University of Vienna, Austria.
J Cancer Res Clin Oncol. 1994;120(12):737-42. doi: 10.1007/BF01194273.
Breast cancer tissue was examined for overexpression of HER-2/neu and p53 oncogene proteins. Samples from 105 breast cancer patients were investigated by Western-blot analysis and their relationship to other established markers and clinical outcome was examined. In 21.0% of the cases HER-2/neu was overexpressed, and in 46.7% the p53 protein level was increased. Expression of these two oncogene products was closely correlated. Overexpression of both oncogenes was associated with larger tumour size and negative hormone receptor. The percentage of HER-2/neu and p53 overexpression was higher in node-positive patients, although statistical evaluation was not significant. While overexpression of HER-2/neu as well as p53 in node-positive patients was associated insignificantly with shorter disease-free survival, a significant difference could be documented when the disease-free survival of patients with overexpression of both oncogene proteins was compared to that of patients with no overexpression.
对乳腺癌组织进行了HER-2/neu和p53癌基因蛋白过表达检测。采用蛋白质免疫印迹分析法对105例乳腺癌患者的样本进行研究，并检测其与其他已确定标志物及临床结局的关系。21.0%的病例中HER-2/neu过表达，46.7%的病例中p53蛋白水平升高。这两种癌基因产物的表达密切相关。两种癌基因的过表达均与肿瘤体积较大及激素受体阴性相关。HER-2/neu和p53过表达的百分比在淋巴结阳性患者中更高，尽管统计学评估无显著差异。虽然淋巴结阳性患者中HER-2/neu和p53的过表达与无病生存期缩短无显著相关性，但当比较两种癌基因蛋白均过表达的患者与无过表达患者的无病生存期时，可发现显著差异。
